利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

60 条记录 (耗时 0.133 秒)

    Expression vectors
    32.
    发明申请
    Expression vectors 有权
    表达载体

    公开(公告)号：US20090320149A1

    公开(公告)日：2009-12-24

    申请号：US12456007

    申请日：2009-06-10

    申请人： Naoya Tsurushita ,  J. Yun Tso

    发明人： Naoya Tsurushita ,  J. Yun Tso

    IPC分类号： A01K67/027 ,  C12N15/11 ,  C07K16/00 ,  C12N15/00 ,  C12N5/06

    CPC分类号： C07K16/00 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/241 ,  C07K16/2866 ,  C07K2319/03 ,  C07K2319/035 ,  C07K2319/30 ,  C07K2319/32 ,  C12N15/85 ,  C12N2840/44 ,  C12N2840/85

    摘要： This present invention provides an expression vector system that uses alternative RNA processing to express in a single cell a polypeptide in both membrane-bound and soluble forms. By incorporating a mimetic structure of the 3′ terminal region of human mu gene and introducing other exogenous genetic elements, an artificial gene can be constructed that is capable of simultaneously expressing membrane-bound and secreted forms of polypeptides in myeloma cells and other cells of the B lymphocyte lineage, as well as in non-B cells. If an immunoglobulin heavy chain is co-expressed with a light chain using this vector, whole antibodies can be produced that are both displayed on the surface of a single cell and secreted into the cell culture supernatant. Membrane-bound antibodies facilitate isolation and expansion of those cells displaying antibodies with desired antigen binding characteristics, while secreted antibodies facilitate identification of antibodies having desired biological function(s).

    摘要翻译： 本发明提供了一种表达载体系统，其使用替代的RNA加工来在单细胞中以膜结合和可溶形式表达多肽。 通过掺入人mu基因的3'末端区域的模拟结构并引入其他外源遗传元件，可以构建人造基因，其能够同时表达骨髓瘤细胞和其它细胞中的多肽的膜结合和分泌形式 B淋巴细胞谱系，以及非B细胞。 如果使用该载体使免疫球蛋白重链与轻链共同表达，则可以产生全部抗体，其均显示在单个细胞的表面并分泌到细胞培养上清液中。 膜结合的抗体促进显示具有所需抗原结合特征的抗体的那些细胞的分离和扩增，而分泌的抗体便于鉴定具有所需生物学功能的抗体。

    Expression vectors
    35.
    发明授权
    Expression vectors 有权
    表达载体

    公开(公告)号：US08969539B2

    公开(公告)日：2015-03-03

    申请号：US12456007

    申请日：2009-06-10

    申请人： Naoya Tsurushita ,  J. Yun Tso

    发明人： Naoya Tsurushita ,  J. Yun Tso

    IPC分类号： C07H21/04 ,  C12N15/13 ,  C12N15/63 ,  C12N15/85 ,  C12N5/10 ,  C07K16/00 ,  C07K16/24 ,  C07K16/28

    CPC分类号： C07K16/00 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/241 ,  C07K16/2866 ,  C07K2319/03 ,  C07K2319/035 ,  C07K2319/30 ,  C07K2319/32 ,  C12N15/85 ,  C12N2840/44 ,  C12N2840/85

    摘要： This present invention provides an expression vector system that uses alternative RNA processing to express in a single cell a polypeptide in both membrane-bound and soluble forms. By incorporating a mimetic structure of the 3′ terminal region of human mu gene and introducing other exogenous genetic elements, an artificial gene can be constructed that is capable of simultaneously expressing membrane-bound and secreted forms of polypeptides in myeloma cells and other cells of the B lymphocyte lineage, as well as in non-B cells. If an immunoglobulin heavy chain is co-expressed with a light chain using this vector, whole antibodies can be produced that are both displayed on the surface of a single cell and secreted into the cell culture supernatant. Membrane-bound antibodies facilitate isolation and expansion of those cells displaying antibodies with desired antigen binding characteristics, while secreted antibodies facilitate identification of antibodies having desired biological function(s).

    摘要翻译： 本发明提供了一种表达载体系统，其使用替代的RNA加工来在单细胞中以膜结合和可溶形式表达多肽。 通过掺入人mu基因的3'末端区域的模拟结构并引入其他外源遗传元件，可以构建人造基因，其能够同时表达骨髓瘤细胞和其它细胞中的多肽的膜结合和分泌形式 B淋巴细胞谱系，以及非B细胞。 如果使用该载体使免疫球蛋白重链与轻链共同表达，则可以产生全部抗体，其均显示在单个细胞的表面并分泌到细胞培养上清液中。 膜结合的抗体促进显示具有所需抗原结合特征的抗体的那些细胞的分离和扩增，而分泌的抗体便于鉴定具有所需生物学功能的抗体。

    Amphiregulin antibodies and their use to treat cancer and psoriasis
    38.
    发明授权
    Amphiregulin antibodies and their use to treat cancer and psoriasis 有权
    双调蛋白抗体及其用于治疗癌症和牛皮癣的用途

    公开(公告)号：US07223393B2

    公开(公告)日：2007-05-29

    申请号：US10774076

    申请日：2004-02-06

    申请人： Nicholas F. Landolfi ,  Naoya Tsurushita ,  Paul R. Hinton ,  Shankar Kumar

    发明人： Nicholas F. Landolfi ,  Naoya Tsurushita ,  Paul R. Hinton ,  Shankar Kumar

    IPC分类号： A61K39/395

    CPC分类号： G01N33/574 ,  A61K47/6855 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/73 ,  G01N2333/485

    摘要： The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.

    摘要翻译： 本发明涉及抗AR抗体，优选具有本文公开的氨基酸序列的人源化单克隆抗体。 本发明包括含有这种抗体的药物组合物。 本发明包括抑制癌细胞生长的方法，其包括向受试者施用此类抗体。 本发明还提供了通过以药学上有效量向所述受试者施用这种抗体来治疗需要这种治疗的受试者中的癌症或牛皮癣的方法。

    Alteration of Fc-fusion protein serum half-lives by mutagenesis
    39.
    发明授权
    Alteration of Fc-fusion protein serum half-lives by mutagenesis 有权
    通过诱变改变Fc融合蛋白血清半衰期

    公开(公告)号：US07217798B2

    公开(公告)日：2007-05-15

    申请号：US10966673

    申请日：2004-10-15

    申请人： Paul R. Hinton ,  Naoya Tsurushita

    发明人： Paul R. Hinton ,  Naoya Tsurushita

    IPC分类号： C12P21/08 ,  C12P21/06 ,  C12P21/04 ,  C07K16/00 ,  C12N15/00

    CPC分类号： C07K14/7151 ,  C07K14/5437 ,  C07K14/70528 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/30

    摘要： The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.

    摘要翻译： 本发明提供了修饰的Fc融合蛋白，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一种不同于此的氨基酸取代 存在于未修饰的Fc融合蛋白中，从而与未修饰的Fc融合蛋白相比，改变了FcRn的结合亲和力和/或血清半衰期。

    Alteration of Fc-fusion protein serum half-lives by mutagenesis
    40.
    发明授权
    Alteration of Fc-fusion protein serum half-lives by mutagenesis 有权
    通过诱变改变Fc融合蛋白血清半衰期

    公开(公告)号：US07732570B2

    公开(公告)日：2010-06-08

    申请号：US11803694

    申请日：2007-05-14

    申请人： Paul R. Hinton ,  Naoya Tsurushita

    发明人： Paul R. Hinton ,  Naoya Tsurushita

    IPC分类号： C07K1/00 ,  C07K16/00 ,  C12P21/08 ,  A61K39/00

    CPC分类号： C07K14/7151 ,  C07K14/5437 ,  C07K14/70528 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/30

    摘要： The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.

    摘要翻译： 本发明提供了修饰的Fc融合蛋白，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一种不同于此的氨基酸取代 存在于未修饰的Fc融合蛋白中，从而与未修饰的Fc融合蛋白相比，改变了FcRn的结合亲和力和/或血清半衰期。